Palisade Bio, Inc.
PALIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Palisade Bio, Inc. focuses on Biotechnology services and products. Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the. The company carries a $342.3M market cap, placing it firmly in the small-cap category. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Market Cap
$342.3M
Beta
1.51
P/E (TTM)
15.15
P/E (Fwd)
-6.90
EPS (TTM)
$0.13
EPS (Fwd)
$-0.29
ROE
-36.4%
ROA
-23.4%
Cash
$132.6M
Total Debt
$0
Free CF
-$5.4M
52W Change
162.7%
Annual Financials
Cash vs Debt
Palisade Bio, Inc. reports $132.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$5.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -36.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.51 means PALI is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Palisade Bio, Inc.'s trajectory.